Michelle M. Mello's Testimony Before the U.S. Senate Committee on Finance
In this testimony presented to the U.S. Senate Committee on Finance, Michelle M. Mello provides recommendations on how Congress can support healthcare organizations and health insurers navigating the uncharted territory of AI tools by imposing some guardrails while allowing the rules to evolve with the technology.
Related Publications
Toward Responsible AI in Health Insurance Decision-Making

This brief proposes governance mechanisms for the growing use of AI in health insurance utilization review.

This brief proposes governance mechanisms for the growing use of AI in health insurance utilization review.
Response to OSTP's Request for Information on Accelerating the American Scientific Enterprise

Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.

Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.
Response to FDA's Request for Comment on AI-Enabled Medical Devices

Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.

Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.
Russ Altman’s Testimony Before the U.S. Senate Committee on Health, Education, Labor, and Pensions

In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.

In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.


